Long-term Immunogenicity and Boostability of the 13-valent Pneumococcal Conjugate Vaccine Followed by the 23-valent Pneumococcal Polysaccharide Vaccine in Adults Receiving Immunosuppressive Therapy and Adults With HIV—3-year Follow-up of a Prospectiv
Only a minority of PWH and patients on immunosuppressive therapy and under half of controls remained seroprotected 3 years after vaccination. As rapid recall responses were limited to PCV serotypes, future research in ICPs should focus on expanded priming schedule with higher-valent PCVs such as PCV20.
Authors
- Ana-Lena Reiners
- Hannah M Garcia Garrido (ORCID: https://orcid.org/0000-0002-8481-5455)
- Sabine Haggenburg (ORCID: https://orcid.org/0000-0003-4095-9307)
- Jenny L Schnyder (ORCID: https://orcid.org/0000-0002-2691-8130)
- Abraham Goorhuis (ORCID: https://orcid.org/0000-0001-7423-6217)
- Bob Meek (ORCID: https://orcid.org/0000-0003-3410-9912)
- Martin P. Grobusch (ORCID: https://orcid.org/0000-0002-0046-1099)
Institutions
- St. Antonius Ziekenhuis (NL)
- Amsterdam University Medical Centers (NL)
- Institute of Infection and Immunity (CA)
- University of Amsterdam (NL)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-08-03
- DOI
- https://doi.org/10.1093/cid/ciaf438
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- ZonMw